Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311491 | 0.91 | SMN1; SMN2 (0.49) | HPGDSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL6687682 | 0.89 | SMN1; SMN2 (0.50) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL8216929 | 0.88 | THRA (0.51) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL7790281 | 0.88 | THRA (0.51) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL30294102 | 0.88 | THRA (0.51) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL8751869 | 0.88 | THRA (0.51) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL8751850 | 0.88 | THRA (0.51) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL8751890 | 0.88 | THRA (0.51) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL8216926 | 0.88 | THRA (0.51) | HPGDSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL8773981 | 0.88 | THRA (0.51) | HPGDSMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112980458-B | Bridged naphthene-containing liquid crystal compound and preparation method and application thereof | 北京八亿时空液晶科技股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-110499161-B | Liquid crystal compound, liquid crystal composition and liquid crystal display device | 石家庄诚志永华显示材料有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114105919-A | Liquid crystal compound and preparation method and application thereof | 北京八亿时空液晶科技股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114105966-A | Liquid crystal compound and preparation method and application thereof | 北京八亿时空液晶科技股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-112980458-A | Bridge-ring alkane-containing liquid crystal compound and preparation method and application thereof | 北京八亿时空液晶科技股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-112980460-A | Liquid crystal compound and preparation method and application thereof | 北京八亿时空液晶科技股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021115155-A1 | LIQUID CRYSTAL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 北京八亿时空液晶科技股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| CN-109207160-B | Liquid crystal compound with negative dielectric anisotropy as well as preparation method and application thereof | 北京八亿时空液晶科技股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-9567526-B2 | Polymerizable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-20140375943-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-6737125-B2 | SUCH AS 8,9-DIFLUORO-7-(4-PENTYLPHENYL)-2-PROPYL-2,3-DIHYDRO-1H -CYCLOPENTA(A)NAPHTHALENE; FOR USE IN AUTOMOBILE INTERIORS | CLARIANT FINANCE (BVI) LIMITED (VG) | 2004-05-18 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| US-20030108684-A1 | Such as 8,9-difluoro-7-(4-pentylphenyl)-2-propyl-2,3-dihydro-1H -cyclopenta(a)naphthalene; for use in automobile interiors | CLARIANT INTERNATIONAL LTD. | 2003-06-12 | — | — | US | disclosed |
| US-6197217-B1 | EXHIBIT A NEGATIVE DIELECTRIC ANISOTROPY VALUE, HAVE AN EXTREMELY HIGH VOLTAGE HOLDING RATIO AND A LOW THRESHOLD VOLTAGE, SMALL DEPENDENCY ON TEMPERATURE, HARDLY EXHIBIT SMECTIC PHASE; EXCELLENT IN MISCIBILITY WITH OTHER LC'S | CHISSO CORPORATION (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0959061-A1 | 3,3'-DIFLUOROBIPHENYL DERIVATIVES, LIQUID CRYSTAL COMPOSITIONS, AND LIQUID CRYSTAL DISPLAY ELEMENTS | CHISSO CORPORATION (JP) | 1999-11-24 | — | — | EP | disclosed |
| US-5977105-A | Compounds | ASTRA PHARMAEUTICALS LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| CN-1208403-A | Compounds | BRITISH ASTRA PHARMACEUTICALS (GB) | 1999-02-17 | — | — | CN | disclosed |
| EP-0865431-A2 | COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997020815-A1 | COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108684-A1 | Such as 8,9-difluoro-7-(4-pentylphenyl)-2-propyl-2,3-dihydro-1H -cyclopenta(a)naphthalene; for use in automobile interiors | SCO2, CYP2F1, OGFOD1 | HPGD 1706/4885SMN1; SMN2 1335/4885NPC1 37/4885 |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | HPGD 1963/4885SMN1; SMN2 3990/4885NPC1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.